USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
22 Feb 2022 | 08:00 AM GMT

Remote Patient Monitoring companies in APAC - Routes to Market

Anchored by:

Dr Bechara Saab
CEO & Chief Scientist
MOBIO INTERACTIVE
Dr Suhina Singh
Co-founder | Chief Executive Officer
JONDA HEALTH

Participants:

Dr Bechara Saab CEO & Chief ScientistMobio Interactive
Dr Bechara Saab
CEO & Chief ScientistMobio Interactive
Dr Suhina Singh Co-founder | Chief Executive OfficerJonda Health
Dr Suhina Singh
Co-founder | Chief Executive OfficerJonda Health
Chandana Fitzgerald President, CommunityHLTH
Chandana Fitzgerald
President, CommunityHLTH
JH
Jennifer Hui Digital and Innovation @ Roche APACRoche
JH
Jennifer Hui
Digital and Innovation @ Roche APACRoche
Wipada Rodtanaporn Chief Strategy Officer, Co-founderDigital Health Hub Co.
Wipada Rodtanaporn
Chief Strategy Officer, Co-founderDigital Health Hub Co.

About this Meeting

Are you working on (or planning to) bringing your Remote Patient Monitoring programs (RPM) to the APAC market? Are you finding gaps and blocks in expanding them in a sustainable way? This meeting is for you, keep reading!

 Over 60% of the world's population lives in the APAC region; this huge population pool combined with the greater use of mobile and digital technologies points to a great opportunity for RPM programs in this market. In this meeting we invite you and your peers to the table for an open conversation focused on the best routes to market for RPM companies in the APAC region. The meeting will have the below themes:

  •  Market size in the APAC region: what is the market opportunity for RPM companies compared to other geographies like the US or Europe? What APAC countries are leading the journey? 
  •  Who is paying for RPM programs in the APAC market? What routes to market have been taken so far (e.g partnerships with payers, employers, pharma, medtech, hospitals, D2C, etc)? 
  •  What are the key considerations to ensure a successful commercial model in the APAC market? How does this vary from country to country? What other factors determine the best route to market (e.g , demographic group, disease, objective of the program, others)?